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Abstract
Tuberculosis (TB) is characterized by extensive pulmonary matrix breakdown. Interleukin-17 (IL-17) is key in host
defence in TB but its role in TB-driven tissue damage is unknown. We investigated the hypothesis that respiratory
stromal cell matrix metalloproteinase (MMP) production in TB is regulated by T-helper 17 (TH-17) cytokines.
Biopsies of patients with pulmonary TB were analysed by immunohistochemistry (IHC), and patient bronchoalveolar
lavage fluid (BALF) MMP and cytokine concentrations were measured by Luminex assays. Primary human airway
epithelial cells were stimulated with conditioned medium from human monocytes infected with Mycobacterium
tuberculosis (Mtb) and TH-17 cytokines. MMP secretion, activity, and gene expression were determined by ELISA,
Luminex assay, zymography, RT-qPCR, and dual luciferase reporter assays. Signalling pathways were examined
using phospho-western analysis and siRNA. IL-17 is expressed in TB patient granulomas and MMP-3 is expressed
in adjacent pulmonary epithelial cells. IL-17 had a divergent, concentration-dependent effect on MMP secretion,
increasing epithelial secretion of MMP-3 (p < 0.001) over 72 h, whilst decreasing that of MMP-9 (p < 0.0001);
mRNA levels were similarly affected. Both IL-17 and IL-22 increased fibroblast Mtb-dependent MMP-3 secretion
but IL-22 did not modulate epithelial MMP-3 expression. Both IL-17 and IL-22, but not IL-23, were significantly
up-regulated in BALF from TB patients. IL-17-driven MMP-3 was dependent on p38 MAP kinase and the PI3K
p110 subunit. In summary, IL-17 drives airway stromal cell-derived MMP-3, a mediator of tissue destruction in
TB, alone and with monocyte-dependent networks in TB. This is regulated by p38 MAP kinase and PI3K pathways.
© 2017 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Introduction
Mycobacterium tuberculosis (Mtb) has evolved adaptive
mechanisms to evade host immunity with such success
that today it is the number 1 infectious killer in the world
and caused 1.3 million deaths in 2016 (http://www.who
.int/tb/publications/global_report/en/). Cavities are
pivotal to the spread of TB but the mechanisms that
drive them are less well understood [1]. Diverse studies
indicate that host matrix metalloproteinases (MMPs)
are key [2,3] and we recently showed that collagen
destruction may be a key initial event triggering caseous
necrosis [4]. MMPs can degrade all ECM components
including type I collagen at neutral pH [5]. HighMMP-9
concentrations correlated with disease severity and the
presence of granulomas in tuberculous pleurisy [6].
A matrix-degrading phenotype in human TB where
MMP activity was relatively unopposed by specific
tissue inhibitors of matrix metalloproteinases (TIMPs)
was first described by our group [7]. MMP-1 and
MMP-3 concentrations are increased in respiratory
secretions of TB patients [8]. In the rabbit model,
MMP-1 expression was greater in TB cavities and
an MMP-1/TIMP imbalance was associated with the
development of cavities containing very high bac-
terial burdens [9]. A study in the zebrafish model
showed that MMP-9 from epithelial cells, induced by
the mycobacterial virulence factor ESAT-6, enhanced
macrophage recruitment [10], thereby implicating
MMPs in immunoregulatory as well as tissue destructive
roles in TB.
Respiratory epithelial and other stromal cells are
central in host defence to Mtb in addition to phago-
cytic cells such as alveolar macrophages. Respiratory
epithelial cells secrete inflammatory mediators such
as chemokines [11,12], interferon-γ (IFN-γ), and
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anti-microbial human β-defensins [13]. MMP-1 and
MMP-9 secretion from bronchial epithelial cells is
up-regulated via TB-dependent cellular networks [14].
Another stromal cell, the lung fibroblast, also secretes
mediators that limit the local growth of Mtb [15].
Such networks between leukocytes and stromal cells
appear key, both in host defence and in driving innate
inflammatory tissue damage.
T-helper 1 (TH-1) cells have historically been thought
to be necessary in the control of Mtb infection but
TH-17 cells have now been identified as pivotal in Mtb
control [16]. IL-17 is a pro-inflammatory cytokine
that functions via mesenchymal and myeloid cells to
induce the secretion of diverse cytokines, chemokines,
anti-microbial peptides, and MMPs [17–19]. Mice with
a genetically inactivated IL-17 receptor were unable to
exert long-term control ofMtb, despite a functional TH-1
response [20]. IL-17 knockout mice failed to develop
mature granulomas in bacillus Calmette–Guérin
(BCG)-infected lung and had impaired protection
from virulent Mtb [21]. Although IL-17 is dispensable
for immunity against laboratory-adapted strains of
Mtb, infection with the hypervirulent W-Beijing strain
HN878 required IL-17 for early immunity [22]. In
cynomolgus macaques, sterile granulomas had a higher
frequency of T cells producing IL-17 [23] and pul-
monary delivery of BCG vaccine triggered a mucosal
immune response orchestrated by IL-17 [24]. Finally,
in a study in the Chinese Han population, genetic poly-
morphisms in IL-17A and IL-17F were associated with
host susceptibility to TB [25].
IL-22, a second TH-17 family cytokine, has both anti-
and pro-inflammatory activity at mucosal interfaces
[26]. IL-22 produced by human NK cells inhibits the
growth ofMtb by enhancing phagolysosomal fusion due
to enhanced expression of calgranulin A [27]. IL-22 was
also produced by human NK cells in TB pleural fluid in
response to BCG and Mtb-related antigens, suggesting
that it might participate in the recall immune response
for Mtb infection [28]. IL-17 and IL-22 function syner-
gistically to induce epithelial mediators such as human
β-defensin-2, S100 and lipocalin-2 [29]. IL-23, a mem-
ber of the IL-12 family, is essential for stabilization and
polarization of lymphocytes towards a TH-17 phenotype
and promotes IL-17 secretion by activated TH-17 cells
[30]. IL23A mRNA was up-regulated in unfractionated
BAL cells from TB patients compared with controls [31]
and pulmonary IL-23 gene delivery with a vaccine adju-
vant augmented the expansion of Mtb-specific CD4+ T
cells which produced IL-17 [32,33], with a simultane-
ous reduction in mycobacterial burden and pulmonary
inflammation.
Therefore, accumulating evidence suggests a cen-
tral role for TH-17 cytokines in host–pathogen inter-
actions in TB. We hypothesized that in TB-dependent
networks, stromal cell MMP secretion is regulated by
TH-17 cytokines. First, we identified IL-17 expression
in lymphocytes around pulmonary granulomas in TB
patients. Next, we showed that IL-17 increased mRNA
expression and secretion of epithelial MMP-3, which
was highly expressed in respiratory epithelial cells in
TB patients. In contrast, IL-17 decreased respiratory
epithelial cell MMP-9 production. Both IL-17 and IL-22
increased fibroblast MMP-3 secretion and we demon-
strated for the first time that both of these cytokines are
elevated in BALF from TB patients. Finally, we investi-
gated the mechanisms involved in IL-17 signalling and
show that p38mitogen-activated protein kinase (MAPK)
and the p110α subunit phosphoinositide 3-kinase (PI3K)
signalling paths are key.
Materials and methods
Further details, including experimental design and sta-
tistical methods, may be found in the supplementary
material, Supplementary materials and methods.
Immunohistochemical analysis of patient biopsies
The project was approved by the Hammersmith
and Queen Charlotte’s and Chelsea Research Ethics
Committee, London (ref 07/H0707/120). Immunohisto-
chemistry (IHC) was performed on paraffin-embedded
lung biopsies. Antibodies were purchased from Abcam,
Cambridge, UK.
Clinical study
BALF samples were collected from patients being rou-
tinely investigated for respiratory symptoms at Nalanda
University Hospitals, Patna, India. The study was
approved by the ethics review board at Nalanda Medical
College and University Hospitals (ref SS/0810/TB).
Samples were centrifuged and sterile-filtered to remove
cellular debris and Mtb [34].
Monocyte purification, infection, and generation
of CoMTb
Primary blood mononuclear cells (PBMCs) were from
two donor buffy coats from healthy donors (National
Blood Transfusion Service, UK). Monocytes were
infected with the Mtb H37Rv strain at a multiplicity of
infection (MOI) of 1. For epithelial cells, Ziehl–Nielsen
staining demonstrated that 30% cells were infected at
a MOI of 10, which is similar to previous reports
[35]. Medium from infected monocytes was termed
conditioned medium from monocytes infected with
Mtb (CoMTb). Control medium was generated in an
identical manner but without infection and was called
CoMCont.
Cell culture and experimental design
Primary small airway epithelial cells (SAECs) and
normal human bronchial epithelial (NHBE) cells
were cultured in bronchial epithelial growth media
(Lonza Biosciences, Basel, Switzerland) and human
MRC-5 fibroblasts were grown in Eagle’s medium
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(Sigma-Aldrich, Gillingham, Dorset, UK), according to
the suppliers’ instructions. Epithelial cells were stimu-
lated with a 1 in 5 dilution of CoMTb and MRC-5 cells
with a 1 in 50 dilution. Supernatants were harvested at
72 h for secretion analysis and mRNA extraction was
performed at 24 h [14,36].
Promoter-reporter assay
Promoter-reporter studies were performed using
FuGENE HD Transfection Reagent and Promega’s
Dual-Luciferase Reporter Assay System (Promega-UK,
Southampton, UK). The MMP-3 promoter (1206 base
pairs) was linked to firefly luciferase and the reference
gene thymidine kinase promoter was linked to Renilla
luciferase.
Phospho-western analysis and gelatin zymography
After electrophoresis, proteins were electro-transferred
to nitrocellulose membranes and probed with a primary
antibody, then washed and incubated with a secondary
antibody. Luminescence was produced using the ECL
system. MMP-9 gelatinolytic activity was detected by
zymography using standard methodology [37].
Small interfering RNA (siRNA) transfection
All siRNAs pools targeted the transcription products
from four alleles of the gene of interest. Conditions
for transfection were optimized using a transfection
control and a negative control (non-targeting siRNA;
supplementary material, Figure S1).
RNA extraction, cDNA synthesis, and reverse
transcription–quantitative polymerase chain
reaction (RT-qPCR)
RNA extraction was performed using the Qiagen
RNeasy Minikit (QIAGEN Ltd, Manchester, UK).
cDNA synthesis was performed using a Qiagen Quanti-
tect reverse transcription kit (QIAGEN Ltd). Real-time
quantitative PCR was performed using the Brilliant II
QPCR master mix on the Stratagene Mx3000P plat-
form (Stratagene, Cambridge, UK). MMP primers and
probes have been described previously [38]. Experi-
mental MMP data were normalized to three reference
genes. Analysis of MMP mRNA expression was first
undertaken by the standard curve method, and results
were corroborated by CT values assessing levels of gene
expression.
Results
IL-17 is expressed in human TB granulomas and has
divergent effects on epithelial cell MMP-3
and MMP-9 secretion
First, we investigated the expression of IL-17 in five TB
and five control human lung biopsy specimens. IL-17
was expressed in TB granulomas (Figure 1A) but not in
control lung biopsies of normal tissue (Figure 1B). As
a positive control, we detected colonic T-lymphocyte
immunoreactivity (supplementary material, Figure
S2A). No staining was seen when the primary anti-
body was omitted as a negative control (supplementary
material, Figure S2B). Next, we investigated MMP
secretion from human distal small airway epithelial
cells (SAECs). MMP-1, MMP-3, and MMP-9 secretion
from SAECs was all increased following stimulation
by CoMTb at a 1 in 5 dilution. MMP-3 secretion
increased 2.2-fold from 534 ± 34 pg/ml to 1171 ± 44
pg/ml (Figure 1C, p = 0.005) and MMP-9 secretion
increased 10.5-fold from 11 446 ± 15 pg/ml to 119 561
± 77 pg/ml (Figure 1D, p = 0.002). MMP-1 secretion
increased 4.5-fold from a baseline of 490 ± 30 pg/ml to
2247 ± 25 pg/ml (Figure 1E, p = 0.008). SAECs con-
stitutively secrete MMP-2 at a baseline which was not
altered significantly by CoMTb (Figure 1F). MMP-8
was detectable but only at very low concentrations
(Figure 1G). MMP-7, MMP-12, and MMP-13 were
almost undetectable (data not shown).
Next, we investigated the effect of IL-17 on MMP
secretion. In SAECs, maximal MMP-3 secretory effect
was observed with 30 ng/ml IL-17 (supplementary
material, Figure S3A) [39,40]. In co-stimulation experi-
ments with CoMTb, IL-17 increased baseline epithelial
MMP-3 secretion from 534 ± 34 pg/ml to 1612 ±
17 pg/ml (p < 0.001), and CoMTb-driven MMP-3
secretion from 1171 ± 44 pg/ml to 4196 ± 28 pg/ml
(Figure 1C, p < 0.001). In contrast, CoMTb-driven
MMP-9 secretion was suppressed by IL-17 from 119
561 ± 77 pg/ml to 7483 ± 50 pg/ml (Figure 1D, p <
0.0001). MMP-9-induced gelatinolysis, measured by
zymography, was similarly decreased by IL-17 (data
not shown). Changes in gene expression were consistent
with secretion data (data not shown). IL-17 did not alter
MMP-1, MMP-2 or MMP-8 secretion from SAECs
(Figure 1E–G). Lastly, we investigated TIMP-1/2
secretion as the MMP/TIMP ratio is functionally impor-
tant in determining net matrix degradation. CoMTb
suppressed TIMP-1 secretion (supplementary material,
Figure S3B, p < 0.5) but IL-17 did not significantly
modulate this. TIMP-2 secretion was also unaffected by
IL-17 (supplementary material, Figure S3C); therefore,
these results confirm that up-regulation of MMP-3 in
TB is unopposed by inhibitor secretion.
MMP-3 is expressed by epithelial cells in TB
and secretion is up-regulated by IL-17 in a TB
network, whereas direct infection with Mtb does
not modulate expression
In TB patient lung biopsies, pulmonary epithelial cells
adjacent to TB granulomas strongly expressed MMP-3
(Figure 2A), whereas minimal staining was observed
in normal lung biopsies (Figure 2B). After confirming
that upper airway epithelial cells (NHBE) and SAECs
had similar secretion profiles, we performed all further
experiments on NHBE cells. Our immunohistochemical
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Figure 1. IL-17 is expressed in granulomas of TB patients and has a divergent effect on epithelial MMP secretion in a TB network. (A) IL-17
is expressed around granulomas in patients with TB. The figure is representative of lung biopsies from five patients with Mtb infection (scale
bar = 200 μm). (B) Control normal lung tissue showed no immunoreactivity for IL-17 (scale bar = 200 μm). (C) MMP-3 secretion increased
2.2-fold after stimulation with CoMTb and this was further augmented four-fold by IL-17. IL-17 also increased the baseline secretion of
MMP-3 from SAECs by three-fold (p < 0.001). (D) CoMTb increased MMP-9 secretion 10.5-fold (p = 0.002), but this was suppressed by
IL-17 (p < 0.0001). (E) MMP-1 secretion from SAECs was augmented 4.5-fold by CoMTb (p < 0.001), but was not altered by IL-17. (F) SAECs
constitutively secrete MMP-2, which was not altered significantly by CoMTb. (G) MMP-8 was augmented by CoMTb but only at very low
concentrations. In the figures, * indicates p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.
studies showed MMP-3 expression by epithelial cells
in the relatively larger airways, which we felt were best
modelled by NHBE cells, and hence we used these
for further studies. In NHBE cells, maximal MMP-3
secretory effect was observed with 10 ng/ml IL-17
(supplementary material, Figure S3D) [41,42]. Kinetic
experiments in NHBE cells showed that the MMP-3
concentration peaked at 72 h when stimulated with
IL-17, after which it declined (Figure 2C, p < 0.001),
and IL-17-driven MMP-3 mRNA accumulation peaked
at 24 h (Figure 2D, p < 0.01). These kinetics are similar
to our published data on MMP-1 and MMP-9 secretion
[14,36]. Next, we investigated the regulation of MMP-3
and MMP-9 by IL-22 and IL-23 and found no change
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Figure 2. MMP-3 is expressed in human respiratory epithelial cells in TB patients and MMP-3 gene expression and secretion are driven
by IL-17. (A) Pulmonary epithelial cells adjacent to TB granulomas express MMP-3. The figure is representative of lung biopsies from five
patients with TB (scale bar = 20 μm). (B) Minimal staining for MMP-3 was observed in five normal lung specimens (scale bar = 20 μm). (C)
Kinetic experiments in NHBE cells demonstrated that MMP-3 secretion increased progressively until 72 h after stimulation with 10 ng/ml
IL-17 (p < 0.001). (D) IL-17-driven MMP-3 mRNA accumulation peaked at 24 h, rising to four-fold above baseline (p < 0.01). (E) Direct
infection of NHBE cells with Mtb at an MOI from 0.1 to 10 did not alter MMP-3 secretion and there was no synergy between Mtb infection
and IL-17 stimulation.
(supplementary material, Figure S4A–D). Direct
infection with Mtb at MOI from 0.1 to 10 had no
significant effect on MMP-3 secretion from NHBE cells
in the presence or absence of IL-17 (Figure 2E). Infec-
tion at a higherMOI did not increase the uptake of bacte-
ria and MMP production remained unchanged (data not
shown).
To further dissect the IL-17 and CoMTb-driven
MMP-3 up-regulation, we performed cytokine and
chemokine analyses in the supernatants from NHBE
cells stimulated with IL-17 alone or in combination
with CoMTb. The cytokines and chemokines analysed
were IL-1β, IL-6, IL-10, TNF-α, IL-1Ra, IFN-α, IFN-γ,
IL-13, IL-15, IL-17, IL-12, IL-5, IL-2, IL-7, IL-2R,
IL-4, RANTES, eotaxin, MIP-1β, MIP-1α, MCP-1,
IP-10, MIG, and CXCL-8. We found that although
TNF-α, IL-1RA, CXCL-8, and MIP-1α were elevated
in both groups, only the CXCL-8 concentration was
significantly different between groups (supplementary
material, Table S1, p < 0.001). Stimulating NHBE cells
with TNF-α alone and in the presence of IL-17 did not
drive MMP-3 secretion (supplementary material, Figure
S5). These experiments demonstrate that the synergy
between multiple mediators drives maximal MMP-3
production from stromal cells in TB.
IL-17 and IL-22 augment TB-dependent MMP-3
secretion from fibroblasts
Next, we investigated MMP secretion from fibrob-
lasts, stromal cells that can secrete high concentra-
tions of MMPs [43]. CoMTb stimulation drove a
concentration-dependent increase in MMP-3 secretion
from MRC-5 fibroblasts at 72 h (Figure 3A). Although
maximal MMP-3 secretion was observed at a CoMTb
dilution of 1 in 5 (p < 0.0001), this was accompanied
with significant cell death. In subsequent experiments,
CoMTb was used at a dilution of 1 in 50, which also
significantly up-regulated MMP-3 secretion (p < 0.01)
with no effect on cell viability. To investigate further,
promoter-reporter studies were performed using a
wild-type construct of the MMP-3 promoter. Acti-
vation in response to CoMTb was detectable at 6 h,
peaking at 24 h, and thereafter remaining stable for 48
h (Figure 3B, p < 0.001).
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Figure 3. IL-17 and IL-22 increase TB-dependent MMP-3 secretion from fibroblasts. (A) CoMTb caused a concentration-dependent
increment in MMP-3 secretion from MRC-5 fibroblasts (p < 0.01). (B) MMP-3 full-length promoter activation in response to CoMTb
was detectable at 6 h, peaking at 24 h (p < 0.001), and thereafter remaining stable for 48 h. Results are expressed as relative luminescence
(RLU) for firefly/Renilla luciferase. (C) IL-17 and (D) IL-22 both increased CoMTb-driven MMP-3 secretion from MRC-5 fibroblasts in a
concentration-dependent manner (p < 0.001 for both cytokines), but neither affected MMP-3 secretion as a single stimulus.
Next, MRC-5 fibroblasts were stimulated with IL-17
alone and in combination with CoMTb. IL-17 further
up-regulated CoMTb-induced MMP-3 secretion from
107 005 ± 6729 pg/ml to 191 829 ± 11057 pg/ml
(Figure 3C, p < 0.001), but did not affect MMP-3 as a
single stimulus. Similarly, IL-22 almost doubled fibrob-
last MMP-3 secretion from 16 694 ± 1734 pg/ml to
27 638 ± 483 pg/ml (Figure 3D, p < 0.001), but did
not affect baseline MMP-3 secretion in the absence of
CoMTb.
IL-17 and IL-22 are up-regulated in TB patient
bronchoalveolar lavage fluid
To examine the relevance of these findings to human TB
infection, we investigated IL-17, IL-22, and IL-23 con-
centrations in BALF from 17well-characterized patients
with confirmed pulmonary TB and 18 well-matched res-
piratory symptomatic patients with other diagnoses that
may cause a clinically similar picture, which we have
previously reported [44]. There were no significant dif-
ferences between the two groups with regard to age,
gender, and smoking history. None of the subjects had a
previous history of TB. The median IL-17 concentration
was increased in TB patients compared with other res-
piratory symptomatic patients (p = 0.02), although the
absolute concentrations detectable in BALF were low
(Figure 4A). The median IL-22 concentration in BALF
from TB patients was four-fold higher than in control
patients (Figure 4B, p = 0.006). IL-23 concentrations
were virtually all below the level of detection in both
control and TB groups (supplementary material, Figure
S6). This demonstrates that the IL-17 expression seen in
lymphocytes by IHC leads to increased concentrations
in bronchial lining fluid.
IL-17-driven MMP-3 secretion is p38
MAPK-dependent
Next, we investigated the mechanisms regulating
IL-17-dependent MMP-3 secretion from NHBE cells.
First, we studied the MAPK pathways. Both CoMTb
and IL-17 as single stimuli caused phosphorylation of
p38MAPK, peaking at 30 min, after which it returned to
baseline. Phosphorylation of p38 was further increased
when cells were co-stimulated with 10 ng/ml IL-17 and
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Figure 4. IL-17 and IL-22 are up-regulated in BALF from patients
with TB. Concentrations of IL-17 and IL-22 were measured in BALF
from 17 TB subjects and 18 well-matched respiratory symptomatic
patients. (A) Median IL-17 concentration was increased in TB
patients compared with other respiratory symptomatic patients (p
= 0.02), although the absolute detectable concentrations were low.
(B) Median IL-22 concentration in TB patients was four-fold higher
than in control patients (p = 0.006) (Mann–Whitney U-test).
CoMTb (Figure 5A). Densitometric analysis confirmed
increased phosphorylation. ERK 1/2 and JNK MAPKs
are constitutively phosphorylated in NHBE cells and
were not investigated further.
Next, we investigated the effect of chemical and
siRNA-mediated inhibition of p38 on IL-17-dependent
MMP-3 secretion. The p38-specific chemical inhibitor
SB203580 suppressed IL-17-driven MMP-3 secre-
tion in a concentration-dependent manner to baseline
(Figure 5B, p < 0.001). Concurrently, inhibition of
IL-17-dependent MMP-3 mRNA accumulation was
also observed (Figure 5C, p < 0.001). Confirming
these data, p38 MAPK-specific siRNA decreased
IL-17/CoMTb-driven MMP-3 secretion by 50%
(Figure 5D, p < 0.01) and mRNA expression to base-
line levels (Figure 5E, p < 0.01). The suppression was
maximal with 30 nM siRNA. Cells were also transfected
with non-targeting siRNA (NT siRNA) and no change
was observed. siRNA knockdown of phospho-p38 was
confirmed by western blotting and at the mRNA level
(supplementary material, Figure S7A, B). Significant
knockdown was observed at 10 nM p38 siRNA and
levels were undetectable with 30 nM siRNA in NHBE
cells stimulated with CoMTb and 10 ng/ml IL-17.
Non-targeting siRNA had no effect on p38 expression.
Similar results with p38 chemical and siRNA-mediated
inhibition were observed in SAECs (data not shown).
In summary, these data show that p38 MAPK signalling
regulates IL-17-driven MMP-3 secretion from NHBE
cells in a TB network.
Epithelial MMP-3 secretion in TB is regulated
by the PI3K p110α subunit and AKT
Finally, we investigated whether the PI3-kinase
(PI3K) pathway had a role in IL-17-driven MMP-3
up-regulation, since this path has been implicated in
the IL-17A-mediated regulation of several other genes
in human airway epithelial cells [39]. The non-specific
PI3K proximal catalytic subunit inhibitor LY294002
suppressed IL-17-dependent MMP-3 secretion to con-
trol concentrations (Figure 6A, p < 0.0001). To identify
the specific p110 catalytic subunit involved, NHBE
cells were transfected with siRNAs specific for the
p110 catalytic subunit isoforms. MMP-3 mRNA was
suppressed to baseline with the p110α-specific inhibitor
(Figure 6B, p < 0.0001). There was no change upon
pre-incubation with non-targeting siRNA, the negative
control. In contrast, p110β subunit-specific inhibition
did not alter MMP production (data not shown). siRNA
knockdown of the p110α subunit was confirmed by
western blotting and at the mRNA level (supplementary
material, Figure S7C, D). Significant knockdown was
observed at 10 nM and levels were undetectable with
30 nM siRNA, with no effect seen with non-targeting
siRNA.
As the γ and δ isoforms are almost exclusively
expressed in leukocytes, they were not investigated.
Downstream of PI3K, inhibition of AKT similarly sup-
pressed MMP-3 secretion to baseline (Figure 6C, p
< 0.0001). Thus, both proximal and distal nodes of
the PI3K signalling pathway regulate IL-17-mediated
MMP-3 gene expression and secretion in TB.
Discussion
We have demonstrated for the first time that IL-17
is expressed within human TB granulomas and that
adjacent epithelial cells express MMP-3. IL-17 causes
up-regulation of MMP-3 gene expression and secretion
from epithelial cells exposed to a monocyte-dependent
infection in vitro network. Since SAECs and NHBE
cells have different immunological roles [45], we first
investigated their secretion profiles and identified these
to be similar. IHC showed epithelial MMP-3 expression
in the relatively larger airways, which we felt were
best modelled by NHBE cells, and hence we used them
for further studies. We have previously shown that
MRC-5 fibroblasts and human lung (HL) fibroblasts
have similar MMP production profiles in a TB network
[43] and therefore we chose to focus on one fibroblast
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Figure 5. IL-17 regulation of MMP-3 secretion is p38 MAP kinase-dependent. (A) Phosphorylation of p38 after 30 min of stimulation was
increased by both CoMTb and IL-17. p38 phosphorylation was significantly increased when cells were co-stimulated with IL-17 and CoMTb.
There was no change in total p38. Densitometric analysis was performed using Scion image software. (B) MMP-3 secretion and (C)MMP-3
mRNA accumulation driven by IL-17 was inhibited in a concentration-dependent manner by SB203580, a specific p38 chemical inhibitor
(p < 0.001 for both protein and mRNA). (D) Transfection of the epithelial cells with p38 siRNA decreased IL-17/CoMTb-driven MMP-3
secretion by 50% (p < 0.01). The suppression was maximal with 30 nM of siRNA (E) Similarly, IL-17-driven MMP-3 mRNA decreased to
baseline by siRNA inhibition of p38 (p < 0.01). Cells were also transfected with non-targeting (NT) siRNA, which had no effect.
cell line for this study. Both TH-17 cytokines, IL-17 and
IL-22, drive MMP-3 secretion from MRC-5 fibroblasts
exposed to CoMTb. In contrast, IL-17 did not modulate
the effects of direct infection by Mtb. The concentra-
tions of both of these cytokines were elevated in BALF
from pulmonary TB patients but not from other patients
with similar respiratory symptoms. We have defined key
mechanisms through which IL-17 regulates MMP-3,
which is a mediator of tissue damage in TB, in part
through its action activating the collagenase MMP-1
[46]. Together, these data define a new role for IL-17
in up-regulating tissue-destructive proteases in TB, in
addition to previously described functions in granuloma
development and control of infection [20,21].
The action of IL-17 to increase baseline and
CoMTb-driven epithelial cell MMP-3 gene expression
and secretion is consistent with other studies. In murine
embryonic fibroblasts, IL-17 regulated chemokine and
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Figure 6. Epithelial MMP-3 secretion is regulated by the
PI3K p110α subunit and AKT. (A) IL-17-dependent MMP-3
secretion was reduced to baseline after incubation of NHBE
cells with LY294002, a non-specific PI3K proximal subunit
inhibitor (p < 0.0001). Suppression was maximal at 10 μM.
(B) siRNA transfection of NHBE cells identified that the p110α
subunit was key in this suppression (p < 0.0001). MMP-3 mRNA
was suppressed to baseline with 30 nM siRNA. Cells were also
transfected with non-targeting (NT) siRNA, which had no effect.
(C) Downstream, inhibition of AKT by a specific inhibitor (AKT
inhibitor VIII) resulted in MMP-3 suppression to baseline. The
effect was dose-dependent and maximal at 2.5 μM of the AKT
inhibitor (p < 0.0001).
MMP (MMP-3, MMP-9, and MMP-13) expression
to recruit both neutrophils and monocytes [47]. IL-17
and MMP-3 were expressed in TB lymphocytes and
lung epithelial cells, but IL-17 did not drive epithelial
MMP-3 when cells were directly infected with Mtb. A
biologically relevant feature of IL-17 is its strong coop-
erative and synergistic effect via mRNA stabilization of
other inflammatory cytokines [48], which may account
for its effect on MMP-3 secretion in the TB network
between epithelial cells and monocytes. In contrast,
CoMTb-driven MMP-9 secretion and gene expression
were suppressed by IL-17 and functional activity of
MMP-9 was also reduced. Oriss et al [49] recently
showed that IL-23-dependent IL-17 gene expression in
lung dendritic cells is negatively regulated by MMP-9
enzymatic activity, suggesting that inhibition of MMP-9
could facilitate a strong TH-17 response, which is
desirable for vaccination against Mtb.
To further dissect the IL-17 and CoMTb-driven
MMP-3 up-regulation, we performed extensive cytokine
and chemokine analyses in the supernatants from stim-
ulated NHBE cells and found that only the CXCL-8
concentration was significantly higher in the TB/IL-17
network. Stimulating NHBE cells with TNF-α alone
and in the presence of IL-17 did not drive MMP-3
secretion. The TNF-α concentration in CoMTb is 157
pg/ml when used at a 1 in 5 dilution (supplementary
material, Table S2). When NHBE cells were stimulated
with 5 ng/ml TNF-α (30-fold more), this was a weak
stimulus to MMP-9 secretion, alone and in combination
with lipoarabinomannan (LAM) [14]. Similarly, TNF-α
alone was a weak stimulus to MMP-1 secretion from
epithelial cells [36]. In a previous study investigating the
direct infection of human macrophages with Mtb, other
stimuli such as LPS, BCG, and individual cytokines
including TNF-α, IL-1β or IFN-γ did not drive MMP-1
production [50]. Thus, the synergy between different
mediators appears key in Mtb-driven MMP production
from stromal cells.
We also demonstrated that MMP-3 secretion and pro-
moter activity were increased in fibroblasts as a result of
a monocyte-dependent network in TB and that this effect
was increased synergistically by both IL-22 and IL-17.
This is consistent with data in rheumatoid arthritis,
where TH-17 cells inducedMMP-1 andMMP-3 produc-
tion [51]. In human cardiac fibroblasts, IL-17 stimulated
MMP-1 expression via p38 and ERK-dependent AP-1,
NF-κB, and C/EBP-β activation [52]. In the lung, fibrob-
lasts can secrete very high MMP-1 concentrations [43].
IL-22 did not drive MMP secretion in epithelial cells
(supplementary material, Figure S3), which may reflect
the divergent signalling paths activated in epithelial cells
compared with fibroblasts. Unlike IL-17, IL-22 signals
mainly via the Stat3 pathway and has a clonogenic and
protective effect on human airway epithelial cells [53].
Next, we investigated whether the TH-17 cytokines
were elevated in BALF from patients with pulmonary
TB. In a study of 17 pulmonary TB patients and 18
matched controls, plasma IL-17 levels were elevated
in patients. IL-17 levels substantially decreased after
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treatment and correlated with both CRP and ESR [54].
Previous studies showed that IL-22 may be detected in
tuberculous BALF, pleural fluid, and pericardial fluid
[55,56]. We confirmed that IL-22 was significantly
up-regulated in BALF from TB patients and identified
for the first time that IL-17 concentrations were also
elevated in TB patients, although concentrations were
low (Figure 4). It has been proposed that low levels
of soluble IL-17 in TB are a result of inhibition of
TH-17 effectors by the TH-1 effectors at the site of dis-
ease [57]. However, IL-17 levels in BALF and pleural
fluid, even in the absence of such an inhibitory TH-1
response, are frequently low or undetectable [56,58],
and IL-17 cell-mediated inflammation is independent of
IL-22 [59]. In contrast, IL-17mRNA expression in pleu-
ral fluid mononuclear cells was increased by the Mtb
peptides ESAT-6 and culture filtrate protein (CFP)-10
[57]. In situ hybridization could be used as a further
method to confirm increased IL-17 expression in the
lungs of TB patients.
Finally, we dissected key pathways regulating
IL-17-dependent MMP-3 secretion. We demonstrated
for the first time that inhibition of p38 MAPK, the
PI3K p110α subunit, and AKT resulted in the abro-
gation of IL-17-driven MMP-3 up-regulation in a
TB network. This finding is consistent with studies
which showed that IL-17 regulates mucosal neutrophil
immunity via chemokines and growth factors [40]. It
has been shown in human airway epithelial cells that
IL-17-mediated induction of IL-19, CXCL-1, CXCL-2,
CXCL-3, CXCL-5, and CXCL-6 human defence genes
was mediated via the PI3K pathway [39]. In airway
epithelial cells, regulation of MMPs in Mtb-dependent
respiratory networks was identified to be via the distal
rapamycin-sensitive PI3K/p70S6K cascade, with the
proximal p110α subunit augmenting MMP production
[60]. IL-17 may enhance the migration of periodontal
ligament fibroblasts by increasing MMP-1 expression
through p38MAPK and NFκB signal transduction path-
ways [61]. IL-17 has been shown to limit Mtb-driven
HIF-1α expression [62], showing that there is a complex
interplay between inflammatory signalling, hypoxia,
and tissue destruction [63].
In summary, we investigated the effect of TH-17
cytokines on epithelial MMP production by immuno-
histochemical analysis of patient biopsies, by inves-
tigating a cellular TB network model and finally by
cytokine analysis of BALF from TB patients. We specif-
ically focused on intercellular networks between lym-
phocytes and airway epithelial cells in TB, and have
shown for the first time that lymphocyte-derived IL-17
drives both epithelial- and fibroblast-derived MMP-3 in
a TB network, whereas direct infection does not. IL-17
was expressed in the lymphocytes associated with TB
granulomas and MMP-3 was expressed in the epithe-
lial cells around these TB granulomas. MMP-3 expres-
sion was regulated by the p38 MAP kinase pathway and
the proximal (p110α subunit) and distal nodes (AKT)
of the PI3K pathway. The effects are MMP-specific as
MMP-9 secretion was down-regulated. On examination
of BALF from patients with TB, IL-17 and IL-22 were
both detectable. Several biologics such as monoclonal
antibodies that neutralize IL-17 signalling are now in
clinical development [64,65]. In the context of TB, mod-
ulating the TH-17 pathway may alter MMP activity,
reduce tissue destruction, and improve outcomes. In
the present era of increasing anti-mycobacterial drug
resistance, host-directed therapy is emerging as a key
paradigm for future TB treatment [66].
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